Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)

Not Applicable

Completed

• Conditions: Obesity
• Interventions: Behavioral: Self-Directed Weight Loss Program; Behavioral: Call-Center Directed (CCD) Weight Loss Program; Behavioral: In-Person Directed (IPD) Weight Loss Program

• Registration Number: NCT00783315
• Lead Sponsor: Johns Hopkins University

Brief Summary

Many people who are obese also have high blood pressure, high cholesterol, or diabetes-all conditions that can increase the risk of heart disease. This study will evaluate two programs that aim to encourage weight loss among obese people who are at risk for developing heart disease.

Detailed Description

High blood pressure, high cholesterol, and diabetes are all conditions that increase a person's risk of developing heart disease. Many people with these conditions are also overweight, and it is recommended that such people lose weight to reduce their risk of heart disease. Previous weight loss studies have mainly examined in-person weight loss programs and not Web- or e-mail-based weight loss programs. In addition, the primary care providers of participants in these previous studies typically had no direct involvement in the programs. This study will compare two weight loss programs-an In-Person Directed (IPD) program, which is primarily comprised of in-person visits with health counselors, and a Call-Center Directed (CCD) program, which uses only telephone, Web sites, and e-mail to contact and counsel participants. These two programs will also be compared against a self-directed weight loss program, which will act as a control group. The ultimate purpose of this study is to evaluate the effectiveness of the IPD, CCD, and self-directed programs at increasing weight loss and reducing risk factors in obese people at risk of developing heart disease.

This study will enroll overweight adults who have high blood pressure, high cholesterol, or diabetes. Participants will attend a baseline study visit for weight and blood pressure measurements. They will then be randomly assigned to participate in one of the following three programs for 2 years.

1. IPD Program: This program will be directed by health counselors from Johns Hopkins University. For Months 1 to 3, participants will attend a group or individual meeting with a counselor each week. For Months 4 to 6, meetings will be held three times a month; after Month 6, meetings will occur twice a month. Some of these meetings may be held over the phone or by e-mail. Participants will keep a food and exercise diary and they will enter their weight and calorie consumption on the study Web site. Study researchers will provide participants' doctors with relevant information on participants' weight loss.

2. CCD Program: This program will be directed by counselors from Healthways, Inc., a company that assists individuals in managing their medical problems. All contacts will occur by phone, e-mail, or the Web; there will be no in-person visits. Participants will be able to review weight loss information on the study Web site. For Months 1 to 3, participants will contact their counselors each week. For Months 4 to 6, contact with study counselors will occur at least once a month; after Month 6, contact with study counselors will occur every other month. Participants will keep a food and exercise diary and they will enter their weight and calorie consumption on the study Web site. Study researchers will provide participants' doctors with relevant information on participants' weight loss.

3. Self-Directed Program: In this program, study staff will meet with participants once at the beginning of the study, at which time participants will receive written information about losing weight. Participants will also receive access to a study Web site that has information about weight loss.

All participants will attend study visits at Months 6, 12, and 24 and at the end of the study, which is anticipated to be in February 2011. Study researchers will also collect information by phone at Month 18. At each study visit, participants will complete questionnaires; provide blood samples; and undergo measurements of weight, waist, and blood pressure. A portion of blood may be stored for future studies; this will be optional.

Study Timeline

• Study Start: 2008-02-01
• Study First Submitted: 2008-10-30
• Study First Submitted QC: 2008-10-30
• Study First Posted: 2008-10-31
• Primary Completion: 2011-02-28
• Study Completion: 2011-02-28
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-31
• Last Update Posted: 2018-09-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 415

Inclusion Criteria

• Hypertension, hypercholesterolemia, and/or diabetes mellitus, all of which are treated with medication, measured in the clinic, or confirmed by primary care provider (systolic blood pressure greater than or equal to 140 mm Hg, diastolic blood pressure greater than or equal to 90 mm Hg, low density lipoprotein cholesterol [LDL-C] greater than or equal to 130 mg/dL, or fasting blood sugar greater than 125 mg/dL)

• BMI of at least 30 to 50 kg/m2 and weight less than or equal to 400 lbs

• Willing to change diet, physical activity, and weight

• Willing to be randomly assigned to any of the study groups

• Patient of a participating doctor

• Patient self-reports two doctor visits in the 12 months before study entry

• Demonstrated use of Web and e-mail

• Access to Internet at least 4 days per week

• People with the following conditions are eligible to enroll in the study with primary care provider approval:

  1. Diabetes mellitus
  2. Prior cardiovascular disease event more than 6 months before study entry
  3. Known stable cardiovascular disease or peripheral vascular disease
  4. Screen positive on Rose Questionnaire

Read More

Exclusion Criteria

• Heart attack, stroke, or atherosclerotic cardiovascular disease (ASCVD) procedure in the 6 months before study entry
• Serious medical condition that is likely to hinder accurate measurement of weight, for which weight loss is not advisable, or that would cause weight loss [e.g., end-stage renal disease (ESRD) on dialysis, cancer diagnosis or treatment in the 2 years before study entry]
• Prior or planned bariatric surgery
• Use of prescription weight loss medication, including off-label drugs (e.g., topiramate, bupropion, byetta) or over-the-counter orlistat in the 6 months before study entry
• Long-term use (in the 6 months before study entry) of medications likely to cause weight gain or prevent weight loss (e.g., corticosteroids, lithium, olanzapine, risperidone, clozapine)
• Unintentional weight loss in the 6 months before study entry (greater than or equal to 5% of body weight)
• Intentional weight loss in the 6 months before study entry (greater than or equal to 5% of body weight)
• Pregnant or breastfeeding in the 6 months before study entry
• Planning to become pregnant in the 2 years after study entry
• Planning to relocate from area in the 2 years after study entry
• Another member of the household is a study participant or study staff member
• Self-reported average consumption of more than 14 alcoholic drinks each week
• Psychiatric hospitalization in the 1 year before study entry
• Unstable angina
• Blood pressure greater than 160/100 mm Hg

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Self-Directed Weight Loss Program	Self-Directed Weight Loss Program (Control Group)
2	Call-Center Directed (CCD) Weight Loss Program	Call-Center Directed (CCD) Weight Loss Program
3	In-Person Directed (IPD) Weight Loss Program	In-Person Directed (IPD) Weight Loss Program

Primary Outcome Measures

Name	Time	Method
Weight	Measured at Month 24

Secondary Outcome Measures

Name	Time	Method
Homeostasis model assessment of insulin resistance (HOMA-IR)	Measured at Month 24
Metabolic syndrome	Measured at Month 24
Lipid levels	Measured at Month 24
Hypertension control	Measured at Month 24
Body mass index (BMI)	Measured at Month 24
Blood pressure	Measured at Month 24
Framingham risk	Measured at Month 24

Trial Locations

Locations (1)

ProHealth; 🇺🇸 Baltimore, Maryland, United States